In the last trading session, 1.45 million shares of the Immunic Inc (NASDAQ:IMUX) were traded, and its beta was 1.50. Most recently the company’s share price was $0.77, and it changed around -$0.05 or -6.46% from the last close, which brings the market valuation of the company to $73.54M. IMUX currently trades at a discount to its 52-week high of $2.11, offering almost -174.03% off that amount. The share price’s 52-week low was $0.56, which indicates that the current value has risen by an impressive 27.27% since then. We note from Immunic Inc’s average daily trading volume that its 10-day average is 2.69 million shares, with the 3-month average coming to 1.38 million.
Immunic Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended IMUX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Immunic Inc is expected to report earnings per share of -0.17 for the current quarter.
Immunic Inc (NASDAQ:IMUX) trade information
Instantly IMUX has showed a red trend with a performance of -6.46% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.8999 on recent trading dayincreased the stock’s daily price by 14.43%. The company’s shares are currently down -23.25% year-to-date, but still down -13.31% over the last five days. On the other hand, Immunic Inc (NASDAQ:IMUX) is -20.14% down in the 30-day period. We can see from the shorts that 4.25 million shares have been sold at a short interest cover period of 2.35 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 84.6% from its current value. Analyst projections state that IMUX is forecast to be at a low of $5 and a high of $5.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 26.01%.
IMUX Dividends
Immunic Inc’s next quarterly earnings report is expected to be released on 2025-May-14.
Immunic Inc (NASDAQ:IMUX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.35% of Immunic Inc shares, and 44.83% of them are in the hands of institutional investors. The stock currently has a share float of 45.45%. Immunic Inc stock is held by 80.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 9.15% of the shares, which is about 8.9 million shares worth $9.88 million.
AVIDITY PARTNERS MANAGEMENT LP, with 9.15% or 8.9 million shares worth $9.88 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
